Navigation Links
Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
Date:12/14/2007

SHANGHAI, China, Dec. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts China Partnership Official Delegation, paid a visit to the company on December 7 in Shanghai, China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Massachusetts China Partnership Official Delegation visitors included representatives from Massachusetts life science industry and academia such as Joshua Schafer Boger, Chief Executive Officer of Vertex Pharmaceuticals, and Jack Martin Wilson, President of University of Massachusetts.

Massachusetts is the U.S.'s epicenter for biotechnology, with over 300 biopharmaceutical companies located in the state. With the intellectual resources of leading universities and healthcare institutions, biotechnology has become one of the most important industries in Massachusetts.

During the meeting between the honorable guests and the management team of the company, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, gave Governor Patrick a brief introduction of the company and hoped for more collaboration opportunities between the two parties for continued expansion of the biopharmaceutical industry.

"I am here to encourage the collaboration that WuXi PharmaTech has with Massachusetts companies such as Vertex, and with enterprises everywhere that have the interest and ability to contribute to the future of healing," commented Governor Patrick in his address. "This collaboration has benefits for both Massachusetts and China, and for the future of health care all over the world. Working together, we will be stronger and more successful than we ever could be working apart."

The Governor added, "As in th
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
3. 2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies
4. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
5. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
6. WuXi PharmaTech Announces Second Quarter 2007 Results
7. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
8. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , SEATTLE, Nov. 20 /PRNewswire-FirstCall/ ...CTIC) announced today that the Ninth Circuit Court...nd ruled that CTI should be allowed to pursue all ...case back to the District Court for trial. CTI fi...er third-party reimbursement consultant for CTI,s ...
(Date:11/19/2009)... , SEATTLE, Nov. 19 O... unaudited financial results for the third quarter...ded September 30, 2009, Omeros reported a net loss...to a net loss of $7.4 million, or $2.54 per share,...ended September 30, 2009, the Company reported a n...
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19... and Decision Resources find that the leading driv... in Europe is broad-spectrum activity against gram...variety of organisms that can cause nosocomial pne...hey look primarily for agents that provide appropr...
(Date:11/19/2009)... InSound is honored by latest ... Newark, CA (PRWEB) November 16, 2009...ldquo;invisible” hearing aid from InSound Me... New Award in the Health category.  &nbs...s designed to reside deep in the hearing canal for...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...: Its more than concentration , Be sure... valid comparison. SPEX conservatively quotes a ...the FluoroMax . In 2001, the average FluoroMax ...ipped with a S/N below 3000:1. Compare this to oth... compare experimental conditions. SPEX calculate...
...n , The brightly-colored coral reefs th...hen vacationers stay in the Caribbean or South Pac... of fish and underwater life. Not only do the reef...larger predators, but also some fish actually surv...otection to plants and animals from the ravages of...
..., , Simultaneously monitoring the...s is necessary to properly assess the effectivenes...ofluorometer allows the user to monitor up to eigh...lengths. Coupling this capability with the proper ...ng biological processes. , , Res...
Other Biology Technology:How to select the best spectrofluorometer 2Fluorescent pigments in living coral 2Fluorescent pigments in living coral 3
(Date:11/19/2009)...the genetic instructions inside corn, one of the b...the most complex sequences of DNA ever analyzed, s...id Schwartz, who was one of more than 100 authors ...maize genome is a true maze full of confusing rep...uencers for years," says Schwartz. , Publication...
(Date:11/19/2009)...he offspring of two inbred strains tend to be supe...gene-level variability that leads to this phenomen...t our ability to custom-tailor crops for specific ...sumption or high glucose content for biomass fuel....ce of the common corn strain B73, University of Mi...
(Date:11/19/2009)...aize, also known as corn, researchers across the U...d pave the way to significant improvements in a pl...eed and fiber around the world. , The new map, a..., charts genetic diversity and recombination acros...arch team, led by U.S. Department of Agriculture s...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 1Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 3Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 4Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 5Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 6Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 1Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3
...odel, a correlation-based statistical method is a ... and pinpoint genes that may be potential cancer t...y research. , The research is important because i... gene connections, a task critical for understandi... appeared this week in the online edition of the P...
...heart attack have long been treated with morphine ...from the Duke Clinical Research Institute has show...her risk of dying. , The researchers call for a r.... Meanwhile, they advise cardiologists to begin tr...relieve pain before resorting to morphine. , In th...
... researchers at the Huntsman Cancer Institute at t...a mutant gene found in up to 30 percent of human t...e important in cell signaling, or communication am...ene" or cancer-causing gene that has been shown to...lon and lung, as well as thyroid cancer and leukem...
Other Biology News:Researchers develop promising new gene network analysis method 2Morphine for Chest Pain Increases Death Risk 2Morphine for Chest Pain Increases Death Risk 3Scientists inhibit cancer gene 2
Sheep Anti-11-DEOXY-CORTICOSTERONE (-OCMO) Polyclonal Antibody, Unconjugated from AbD Serotec
Equine Immunoglobulin G from Equitech-Bio
Mouse Anti-Human IFN-Gamma RC2 (CD118) Non-Neutralizing Monoclonal Antibody, Unconjugated, Clone MMHGR-2 from PBL InterferonSource
Rat CINC-2 beta, Unconjugated from R&D Systems
Biology Products: